Gilead Sciences Inc. is once again in the middle of a high stakes patent brawl as ViiV Healthcare claims Gilead's new HIV combination therapy Biktarvy (BIC/TAF) is insubstantially different from ViiV's dolutegravir.
ViiV filed a patent infringement suit against Gilead in the US District Court for the District of Delaware on...





